

Urgent Field Safety Notice

Cryptococcal Antigen Lateral Flow Assay (CrAg® LFA)

Ref# CR2003, Lot #s F1011097, F1011096, F1011095, F1011094, and F1011093 FSCA #: 1627497-2022-001a

Field Safety Corrective Action

January 3, 2022

Dear IMMY CrAg® LFA Customer,

Details on affected devices:

The purpose of this letter is to advise you that IMMY is voluntarily performing a Field Safety Corrective Action (FSCA) on the Cryptococcal Antigen Lateral Flow Assay (Ref# CR2003, Lot #s F1011097, F1011096, F1011095, F1011094, and F1011093), which were distributed to customers between November 12, 2021 and December 27, 2021. Our records indicate you have received one or more of the affected lots.

Reason for the FSCA:

As part of post-market surveillance activities, the above devices were found to have reduced specificity (90% now versus 99% before). There have been no complaints, reports of patient injury or death.

This FSCA does not affect any other lots of the CrAg® LFA (Ref# CR2003).

Risk to Health:

The health risk only applies to patients with positive test results. A small number of samples with positive test results may be false positives, which may cause some patients to initiate unnecessary anti-fungal therapy.

Samples with negative test results are NOT affected. The negative predictive value remains high at nearly 100%.

How to recognize that the device may fail:

It is not possible to distinguish between a true positive and false positive result.

Actions to be taken by you, the customer:

- 1. **Immediately** identify and segregate any affected kits you have in your inventory to prevent them from being used.
- 2. Complete the attached Acknowledgement and Receipt Form (pages 3 and 4 below) even if you do not have any affected stock remaining in your possession. Note: The form is a fillable PDF. You can save it to your computer, fill out electronically and attach to an email. Return the completed form to your distributor, if applicable, or IMMY using one of the methods below:

Rev. 2 Page 1 of 4

- o Email it to your distributor, if applicable
- o Email directly to IMMY at customerservice@immy.com
- Mail directly to IMMY:

Attn: Joy Pelfrey IMMY, Inc. 2701 Corporate Centre Dr Norman, OK USA 73069

- 3. Ensure relevant staff members are informed of this recall, including <u>relevant clinicians</u>. Clinicians should review all positive results from affected lots.
- 4. If you have supplied any potentially affected product to another organization, please advise that organization of this recall and send them this notification. Please contact us so we can follow up with them.
- 5. In case product is in transit, display this letter in a prominent place for one month.

Product Replacement:

To request a free-of-charge replacement, please notify your distributor, if applicable, or IMMY's Customer Service (customerservice@immy.com) and a new lot of CrAg® LFA (Ref# CR2003) will be shipped as quickly as possible. Note: IMMY will not be able to ship replacement product until we have received the completed "Acknowledgement and Receipt Form."

<u>Before contacting customer service, please have the following information available</u>: approval to receive a no-charge replacement and/or a no-charge PO and the shipping information, including an attention line.

Type of Action by the IMMY:

IMMY is immediately notifying all users of the decrease in specificity. The source for the false-positive has been identified and is being remediated.

Other Information:

If you have any questions, do not hesitate to contact IMMY by calling 1-405-360-4669 Monday through Friday 8:30 AM to 5:00 PM Central Standard Time or emailing customerservice@immy.com.

The undersigned confirms that this notice has been notified to the appropriate Regulatory Agencies.

Authorized by:	
lame: Joy Pelfrey, MPH	
ignature:	
itle: VP of Regulatory Affairs & Quality Assurance	

Rev. 2 Page 2 of 4



IMMY CrAg® LFA Field Safety Corrective Action Ref #: CR2003

Acknowledgement and Receipt Form

Response is required before replacements can be sent.

<u>Customer</u>	Information:				
Facility Nar	ne:				
Street Addr	ess:				
City, State,	Country:				
Phone Num	nber:				
Please com	Inventory Recorplete the table below any kits have been IMMY's Catalog Number	ow. Report your in	Quantity of kits in inventory (opened & unopened)	Quantity of kits	hat is affected Quantity of kits completely used
			a unopeneuy		useu
CrAg® LFA	CR2003				
ship them.	cate if you will requ	nt kits. Please send the same address	ts and if yes, the num me (qty as all other orders.		d and where to
	Il NOT need replac	Terre dudi ess.			

Rev. 2 Page 3 of 4

<u>Incidences:</u>	
Are you aware of	any incidences associated with the affected product? Yes No
If yes, please exp	lain:
Additional Respo	onse:
	any additional information, if needed.
Acknowledgeme	nt
	inderstood the Field Safety Notice for the CrAg® LFA (Ref #: CR2003) including the
	ken by you." I have ensured that all personnel, both within our company and
to do when a def	pany, have been notified of the potential defects, how to identify a defect, and what fect is identified
to do When a der	eet is identified.
Signature	Date:
No. of Title	
Name/Title	
Telephone	
Email address	

Please **immediately** complete <u>even if you do not have any affected stock</u> and return it to your distributor, if applicable or IMMY using any of the methods below:

- o Email it to your distributor, if applicable
- o Email directly to IMMY at customerservice@immy.com
- Mail directly to IMMY:

Attn: Joy Pelfrey IMMY, Inc. 2701 Corporate Centre Dr Norman, OK USA 73069

Rev. 2 Page 4 of 4